Ag2R la Mondiale Gestion D'Actifs 13F: Adds $3.1M to ABBV Stake
Key Points
- Ag2R la Mondiale Gestion D'Actifs now holds 89,335 shares of AbbVie, reflecting a 15.0% increase from 77,661 shares previously.
- The stock recently traded around $286.74, which is about equal to its closing price on the filing date of October 26.
- AbbVie is currently valued at approximately $506.7 billion and has a forward P/E ratio of 17.7, indicating strong market interest.
Get AbbVie text alerts
We text you when insiders, Congress, analysts or big funds move on $ABBV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AbbVie Inc. alert may contain errors. Disclosures
On October 26, 2026, Ag2R la Mondiale Gestion D'Actifs boosted its position in AbbVie Inc. (ABBV) by 11,674 shares, bringing its total to 89,335 shares valued at about $23.4 million. This information comes from the fund's latest Form 13F filing with the SEC.
Ag2R la Mondiale Gestion D'Actifs's holdings in AbbVie now represent 1.54% of its total reported 13F value of about $1.52 billion, making it the 13th largest position in the fund's portfolio. The increase of 11,674 shares marks a 15.0% rise from the 77,661 shares previously held.
ABBV
AbbVie Inc.
Other Institutional Activity in AbbVie
Vest Financial reduced its holdings in AbbVie by 43,631 shares, ending with 224,688 shares worth about $58.8 million. Sumitomo Mitsui DS Asset Management Company cut its position by 32,919 shares, now holding 291,632 shares valued at roughly $76.3 million. In contrast, AlphaStar Capital Management added 2,299 shares, increasing its stake to 19,380 shares worth about $5.1 million.
AbbVie Inc. Stock Up 0.4%
As of October 26, AbbVie shares closed at $286.74, which is about equal to the price on that day. The stock is currently trading above its 50-day and 200-day moving averages by 7.4% and 21.6%, respectively, but is slightly below its 52-week high of $291.40.
Recent Earnings
AbbVie reported trailing twelve-month revenue of approximately $64.4 billion, with a net margin of 9.8%. The next earnings report is set for October 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 analysts raised price targets.
-
EPS & revenue
EPS met estimates. Revenue met estimates.
-
Profit surprise
EBITDA missed by 42 percent. Operating income missed by 72 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
4 target raises.
-
Earnings quality
Gross margin up 1.9 points. Operating margin up 3.6 points. Positive free cash flow.
Earnings Call Summary
AbbVie delivered strong first quarter results with $15 billion in sales and earnings per share of $2.65, beating expectations. Skyrizi sales hit $4.5 billion with 29 percent growth in psoriasis and inflammatory bowel disease markets. Rinvoq brought in $2.1 billion with 20 percent growth across rheumatology and gastroenterology, and the company is preparing to launch the drug in alopecia areata and vitiligo later this year.
Guidance The company raised full year earnings per share guidance to between $14.08 and $14.28, up $0.12. They now expect about $67.3 billion in total sales for the year. They also raised guidance for second quarter to about $16.7 billion in revenue and earnings per share between $3.74 and $3.78.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Dividend
AbbVie pays an annual dividend of $6.92 per share, resulting in a dividend yield of approximately 2.41%.
Insider Buying and Selling at AbbVie Inc.
Since February 2026, several insiders have sold shares of AbbVie. Perry C. Siatis, General Counsel, sold 22,381 shares on February 25 at an average price of $230, totaling about $5.1 million. Another officer, Nicholas Donoghoe, sold 32,710 shares on August 14 at $250 each, bringing in about $8.2 million.
Analysts Set New Price Targets
On October 21, Barclays maintained an Overweight rating on AbbVie with a new price target of $325, up from $300. Goldman Sachs also maintained a Neutral rating with a target of $294, increased from $258. The consensus rating on AbbVie remains strong, with a mean price target of $284.79 and 28 analyst opinions supporting a buy recommendation.
About AbbVie
AbbVie Inc. is a biopharmaceutical company focused on developing and selling medicines and therapies worldwide. The company produces treatments for various conditions, including autoimmune diseases and cancers, which positions it well within the healthcare sector.
Bottom Line
Investors will be watching AbbVie closely, especially with the upcoming earnings report on October 30, 2026. The recent boost by Ag2R la Mondiale Gestion D'Actifs highlights continued interest in AbbVie amid fluctuating market conditions.
Related Filing Alerts
Source: Ag2R la Mondiale Gestion D'Actifs's 13F filing on $ABBV (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts